In yesterday’s Wall Street session, Invesco Ltd (NYSE:IVZ) shares traded at $16.05, up 0.31% from the previous session.
IVZ stock price is now 1.13% away from the 50-day moving average and 2.84% away from the 200-day moving average. The market capitalization of the company currently stands at $7.21B.
With the price target of $21, TD Cowen recently initiated with Outperform rating for Invesco Ltd (NYSE: IVZ). On December 14, 2023, Keefe Bruyette Upgraded its previous ‘Mkt Perform’ rating to ‘Outperform’ on the stock increasing its target price from $15.50 to quote $20, while ‘BMO Capital Markets’ rates the stock as ‘Market Perform’
In other news, Invesco Realty, Inc., 10% Owner bought 796,323 shares of the company’s stock on Oct 02 ’23. The stock was bought for $20,000,000 at an average price of $25.12. Upon completion of the transaction, the 10% Owner now directly owns 1,052,487 shares in the company, valued at $16.89 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 05 ’23, 10% Owner Invesco Realty, Inc. bought 2,800,000 shares of the business’s stock. A total of $70,000,000 was incurred on buying the stock at an average price of $25.00. This leaves the insider owning 853,400 shares of the company worth $13.7 million. A total of 2.11% of the company’s stock is owned by insiders.
During the past 12 months, Invesco Ltd has had a low of $12.48 and a high of $18.71. The fifty day moving average price for IVZ is $15.85 and a two-hundred day moving average price translates $15.61 for the stock.
The latest earnings results from Invesco Ltd (NYSE: IVZ) was released for Dec, 2023. According to the Asset Management Company, earnings per share came in at $0.47, beating analysts’ expectations of $0.4 by 0.07. This compares to $0.41 EPS in the same period last year. The net profit margin was -5.77% and return on equity was -0.65% for IVZ. The company reported revenue of $1.41 billion for the quarter, compared to $1.44 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -2.08 percent. For the current quarter, analysts expect IVZ to generate $1.09B in revenue.
